TrialRMD open2023

Phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group study of ustekinumab in Japanese patients with active polymyositis and dermatomyositis who have not adequately responded to one or more standard-of-care treatments.

Kimito Kawahata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.